SCHEMBL6927385

SCHEMBL6927385

Clc1ccc(CC2CCNCC2)c(Oc2ccccc2)c1

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 4/20 0.48
HTR1A P08908 2/20 0.48
SLC6A2 P23975 2/20 0.48
SLC6A3 Q01959 2/20 0.48
HTR2C P28335 8/20 0.45
HTR2B P41595 8/20 0.45
GBA1 P04062 1/20 0.45
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTR2A P28223 1/20 0.42
KCNH2 Q12809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6927980 0.87 HTR2C (0.57) SLC6A4HTR1ASLC6A2SLC6A3HTR2C
SCHEMBL7526768 0.83 SLC6A4 (0.56) SLC6A4HTR1ASLC6A2SLC6A3GBA1
SCHEMBL6927951 0.83 SLC6A4 (0.63) SLC6A4HTR1ASLC6A2SLC6A3HTR2C
SCHEMBL16657602 0.81 FPR2 (0.52) SLC6A4SLC6A2SLC6A3HTR2CHTR2A
Hydrochloric Acid SCHEMBL28086978 0.80 FPR2 (0.51) SLC6A4SLC6A2SLC6A3HTR2CHTR2A
SCHEMBL6929202 0.79 HTR2C (0.52) SLC6A4HTR1ASLC6A2SLC6A3HTR2C
SCHEMBL30933777 0.77 PRMT5 (0.46) SLC6A4HTR1ASLC6A2SLC6A3HTR2C
Hydrochloric Acid SCHEMBL30933829 0.76 PRMT5 (0.45) SLC6A4HTR1ASLC6A2SLC6A3HTR2C
SCHEMBL6927769 0.76 SLC6A4 (0.56) SLC6A4HTR1ASLC6A2SLC6A3HTR2C
SCHEMBL6925382 0.76 SLC6A4 (0.48) SLC6A4HTR1ASLC6A2SLC6A3GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6518284-B2 For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) 2003-02-11 US claimed
US-20020038031-A1 New 4 - substituted piperidines ORJALES VENERO AURELIO (ES) 2002-03-28 US claimed
EP-1002794-A1 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) 2000-05-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038031-A1 New 4 - substituted piperidines ADRA2C, ADRB2, ADRB1 SLC6A4 11/4885HTR1A 16/4885SLC6A2 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.